Profile data is unavailable for this security.
About the company
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cell therapy platform, and biologic therapies for retinal diseases. The Company is developing its modifier gene therapy platform, inclusive of OCU400, OCU410, and OCU410ST, for the treatment of multiple inherited retinal disease (IRDs), including retinitis pigmentosa (RP), Leber congenital amaurosis (LCA), Stargardt disease and multifactorial diseases such as dry age-related macular degeneration (dAMD) and geographic atrophy (GA). It is developing an inhalation-based mucosal vaccine platform based on a novel ChAd vector, which includes OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine.
- Revenue in USD (TTM)8.19m
- Net income in USD-45.87m
- Incorporated2006
- Employees65.00
- LocationOcugen Inc11 GREAT VALLEY PARKWAYMALVERN 19355United StatesUSA
- Phone+1 (484) 328-4701
- Fax+1 (302) 655-5049
- Websitehttps://ocugen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lexeo Therapeutics Inc | 0.00 | -77.22m | 264.49m | 58.00 | -- | 1.60 | -- | -- | -2.81 | -2.81 | 0.00 | 4.99 | 0.00 | -- | -- | 0.00 | -60.10 | -- | -68.82 | -- | -- | -- | -- | -- | -- | -- | 0.0097 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
| Heron Therapeutics Inc | 136.36m | -48.13m | 265.42m | 126.00 | -- | -- | -- | 1.95 | -0.3249 | -0.3249 | 0.9094 | -0.2503 | 0.6503 | 1.08 | 1.81 | 1,082,230.00 | -22.95 | -53.55 | -38.15 | -71.24 | 65.49 | 52.52 | -35.29 | -170.12 | 1.85 | -- | 1.34 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Acrivon Therapeutics Inc | 0.00 | -69.00m | 265.43m | 58.00 | -- | 1.23 | -- | -- | -2.77 | -2.77 | 0.00 | 6.98 | 0.00 | -- | -- | 0.00 | -35.33 | -- | -37.06 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
| MacroGenics Inc | 141.33m | -97.62m | 273.02m | 339.00 | -- | 2.27 | -- | 1.93 | -1.57 | -1.57 | 2.26 | 1.91 | 0.4676 | 3.24 | 8.30 | 416,899.70 | -32.30 | -37.76 | -39.53 | -45.53 | 95.07 | -- | -69.07 | -133.96 | 3.69 | -93.94 | 0.00 | -- | -61.33 | -0.4606 | 92.44 | -- | -41.13 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -88.51m | 274.65m | 20.00 | -- | -- | -- | -- | -2.52 | -2.52 | 0.00 | -0.2208 | 0.00 | -- | -- | 0.00 | -77.89 | -38.44 | -81.83 | -39.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 54.16 | -- | -- | -- |
| Fate Therapeutics Inc | 12.32m | -175.72m | 275.58m | 181.00 | -- | 0.694 | -- | 22.37 | -1.71 | -1.71 | 0.1185 | 3.49 | 0.0221 | -- | 6.35 | 68,049.73 | -31.56 | -31.82 | -33.99 | -36.05 | -- | -- | -1,426.67 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Abeona Therapeutics Inc | 0.00 | -52.60m | 277.21m | 84.00 | -- | 3.64 | -- | -- | -2.13 | -2.13 | 0.00 | 1.76 | 0.00 | -- | -- | 0.00 | -56.09 | -53.22 | -65.23 | -65.81 | -- | -- | -- | -1,894.25 | -- | -- | 0.2004 | -- | 147.52 | 3.14 | -24.63 | -- | -55.74 | -- |
| Zentalis Pharmaceuticals Inc | 40.56m | -194.65m | 281.59m | 168.00 | -- | 0.736 | -- | 6.94 | -2.75 | -2.75 | 0.5719 | 5.38 | 0.0729 | -- | 15.94 | 241,428.60 | -34.99 | -47.40 | -39.16 | -54.18 | -- | -- | -480.07 | -- | -- | -- | 0.00 | -- | -- | -- | -23.39 | -- | 20.76 | -- |
| ADC Therapeutics SA | 66.75m | -214.86m | 283.30m | 273.00 | -- | -- | -- | 4.24 | -2.55 | -2.55 | 0.7802 | -1.36 | 0.1519 | 0.2704 | 2.86 | 244,490.80 | -47.51 | -48.41 | -56.37 | -55.63 | 92.99 | -- | -312.84 | -308.62 | 5.90 | -4.63 | 1.44 | -- | -66.86 | 127.56 | -52.78 | -- | 5.42 | -- |
| Ocugen Inc | 8.19m | -45.87m | 283.89m | 65.00 | -- | 15.00 | -- | 34.66 | -0.1785 | -0.1785 | 0.0319 | 0.0658 | 0.1265 | -- | -- | 126,015.40 | -78.54 | -83.56 | -103.70 | -97.79 | -- | -- | -620.91 | -2,921.94 | -- | -- | 0.1445 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Zura Bio Ltd | 0.00 | -27.94m | 292.09m | 14.00 | -- | 1.86 | -- | -- | -0.4944 | -0.4944 | 0.00 | 2.46 | 0.00 | -- | -- | 0.00 | -23.00 | -- | -30.30 | -- | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -2,050.99 | -- | -- | -- |
| Atea Pharmaceuticals Inc | 0.00 | -176.00m | 295.48m | 75.00 | -- | 0.6201 | -- | -- | -2.10 | -2.10 | 0.00 | 5.64 | 0.00 | -- | -- | 0.00 | -30.97 | -5.90 | -32.19 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Biomea Fusion Inc | 0.00 | -144.01m | 296.43m | 107.00 | -- | 3.90 | -- | -- | -4.00 | -4.00 | 0.00 | 2.10 | 0.00 | -- | -- | 0.00 | -85.85 | -- | -98.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -43.29 | -- | -- | -- |
| Poseida Therapeutics Inc | 88.46m | -112.77m | 299.13m | 337.00 | -- | 4.92 | -- | 3.38 | -1.19 | -1.19 | 0.9296 | 0.6265 | 0.3051 | -- | 7.27 | 268,066.70 | -38.89 | -40.70 | -52.75 | -47.72 | -- | -- | -127.48 | -233.49 | -- | -13.14 | 0.4916 | -- | -50.42 | -- | -92.85 | -- | 19.01 | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 302.52m | 203.00 | -- | 0.559 | -- | 1.59 | -0.2824 | -0.2824 | 3.29 | 9.29 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | -- | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
Data as of Nov 08 2024. Currency figures normalised to Ocugen Inc's reporting currency: US Dollar USD
20.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Sep 2024 | 16.95m | 5.89% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 16.51m | 5.74% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 15.82m | 5.50% |
| Geode Capital Management LLCas of 30 Jun 2024 | 5.90m | 2.05% |
| Rafferty Asset Management LLCas of 30 Jun 2024 | 1.08m | 0.37% |
| Corient Private Wealth LLCas of 30 Jun 2024 | 900.13k | 0.31% |
| Charles Schwab Investment Management, Inc.as of 30 Jun 2024 | 776.02k | 0.27% |
| Goldman Sachs & Co. LLC (Private Banking)as of 30 Jun 2024 | 759.44k | 0.26% |
| BlackRock Investment Management LLCas of 30 Jun 2024 | 686.67k | 0.24% |
| Group One Trading LPas of 30 Jun 2024 | 651.38k | 0.23% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
